Dongwha Pharm.Co.,Ltd

KSE 000020.KS

Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2023: 7.59%

Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) is 7.59% for the year ending December 31, 2023, a 13.82% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 6.67%, a -6.87% change year over year.
Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 7.16%, a -22.91% change year over year.
Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 9.29%, a 76.57% change year over year.
Dongwha Pharm.Co.,Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 5.26%, a 12.16% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KSE: 000020.KS

Dongwha Pharm.Co.,Ltd

CEO	Mr. Doh Joon Yoon
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	FastFive Tower
Employees	792
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Dongwha Pharm Co., Ltd. manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and teeth, hepatic protector, nutrient, tonic, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company was founded in 1897 and is based in Seoul, South Korea.

Key trends

Past 5 years